Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Fernandez MC, Escribano A, Mateo AI, Parthasarathy S, Martin de la Nava EM, Wang X, Cockerham SL, Beyer TP, Schmidt RJ, Cao G, Zhang Y, Jones TM, Borel A, Sweetana SA, Cannady EA, Stephenson G, Frank S, Mantlo NB. Fernandez MC, et al. Among authors: cannady ea. Bioorg Med Chem Lett. 2012 May 1;22(9):3056-62. doi: 10.1016/j.bmcl.2012.03.075. Epub 2012 Mar 28. Bioorg Med Chem Lett. 2012. PMID: 22497761
Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB. Cao G, et al. Among authors: cannady ea. J Lipid Res. 2011 Dec;52(12):2169-2176. doi: 10.1194/jlr.M018069. Epub 2011 Sep 25. J Lipid Res. 2011. PMID: 21957197 Free PMC article.
Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
Escribano A, Mateo AI, Martin de la Nava EM, Mayhugh DR, Cockerham SL, Beyer TP, Schmidt RJ, Cao G, Zhang Y, Jones TM, Borel AG, Sweetana SA, Cannady EA, Mantlo NB. Escribano A, et al. Among authors: cannady ea. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3671-5. doi: 10.1016/j.bmcl.2012.04.042. Epub 2012 Apr 13. Bioorg Med Chem Lett. 2012. PMID: 22543028
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Genin MJ, Bueno AB, Agejas Francisco J, Manninen PR, Bocchinfuso WP, Montrose-Rafizadeh C, Cannady EA, Jones TM, Stille JR, Raddad E, Reidy C, Cox A, Michael MD, Michael LF. Genin MJ, et al. Among authors: cannady ea. J Med Chem. 2015 Dec 24;58(24):9768-72. doi: 10.1021/acs.jmedchem.5b01161. Epub 2015 Dec 2. J Med Chem. 2015. PMID: 26568144 Clinical Trial.
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A. Hamdouchi C, et al. Among authors: cannady ea. J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11. J Med Chem. 2016. PMID: 27749056
Discovery of potent small-molecule inhibitors of lipoprotein(a) formation.
Diaz N, Perez C, Escribano AM, Sanz G, Priego J, Lafuente C, Barberis M, Calle L, Espinosa JF, Priest BT, Zhang HY, Nosie AK, Haas JV, Cannady E, Borel A, Schultze AE, Sauder JM, Hendle J, Weichert K, Nicholls SJ, Michael LF. Diaz N, et al. Nature. 2024 May;629(8013):945-950. doi: 10.1038/s41586-024-07387-z. Epub 2024 May 8. Nature. 2024. PMID: 38720069 Free PMC article.
22 results